

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60790	INTERNATIONAL APPLICATION NO. PCT/US2004/008026
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICANT Busch-Petersen et al.	
(Use several sheets if necessary)		FILING DATE <u>Herewith</u>	GROUP 1624
		Sept. 14, 2006	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

/B.C./	AUSTIN et al, Novel 2,3,4,5-Tetrahydro-1H-3-benzazepine with High Affinity and Selectivity for the Dopamine D <sub>sub.3</sub> Receptor, Bioorganic & Medicinal Chemistry Letters, 20 November 2000, Vol. 10, No. 22, pages 2553-2555, especially pages 2554 and 2555.
/B.C./	MACDONALD et al., Design and Synthesis of trans-3-((3-(3-(5-Methyl-1,2,4-oxadiazolyl)-phenyl)carbomido)cyclohexyl)ethyl-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D <sub>sub.3</sub> Receptor Antagonist, Journal of Medicinal Chemistry, 06 November 2003, Vol. 46, No. 23, pages 4952-4964, especially pages 4956 and 4957.

EXAMINER /Brenda Coleman/ DATE CONSIDERED 09/28/2008

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.